Navigation Links
Safety and Efficacy of OrbusNeich's Genous™ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
Date:1/10/2011

HONG KONG, Jan. 10, 2011 /PRNewswire/ -- Data from patients who are considered high-risk due to underlying clinical conditions and who cannot be treated with drug eluting stents (DES) and the accompanying requirement of long-term dual antiplatelet therapy (DAPT) showed positive safety and short- and long-term clinical outcomes following treatment with OrbusNeich's Genous Stent, according to a study published online in EuroIntervention (published-ahead-of-print, August 2010).  

Known contraindications for DAPT include hypersensitivity or allergy to aspirin, a hemorrhagic risk, or a planned surgery shortly after percutaneous coronary intervention (PCI) that would require cessation of DAPT.

In the study, the major adverse cardiac events (MACE) free survival rate in patients treated with the Genous Stent was 80.6% after one year.  Between year one and year two, no additional MACE were observed. In patients who underwent surgical treatment shortly after PCI, no perioperative MACE or thrombotic events occurred.  Despite a very short period of DAPT use of 15 to 30 days, there were no cases of sub-acute, late or very late stent thrombosis in treated patients. The cumulative incidence of cardiac death was 1.6%, which is low considering the high risk patient population.

"The Genous Stent is an important and extremely attractive option for interventional cardiologists to safely manage high-risk patients who are contraindicated for prolonged DAPT and, therefore, should not receive a DES," said Paolo Scacciatella, M.D., Ph.D., of the Molinette Hospital Turin, Italy, and principal investigator of the study.  "This is the first study that demonstrates the feasibility and efficacy of the Genous Stent in this particular segment of patients who are challenging to treat."

Emanuele Meliga, M.D., Ph.D., FESC, of Ordine Mauriziano Hospital in Turin, Italy, and corresponding author of the publication added, "We have observe
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
9. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
10. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... YORK , April 27, 2015 Harwood ... against the board of directors of Aerie Pharmaceuticals, Inc. ... whether the board has breached its fiduciary duties to ... issued a press release announcing results from its first ... the press release disclosed that in the trial, Rhopressa ...
(Date:4/27/2015)... YORK , April 27, 2015 Bronstein, ... behalf of purchasers of the securities of Celladon Corporation ... are advised to contact Peretz Bronstein or ... info@bgandg.com or 212-697-6484. The investigation ... directors have violated Sections 10(b) and 20(a) of the ...
(Date:4/27/2015)... 27, 2015  Eiger BioPharmaceuticals, Incorporated today announced the ... lonafarnib in patients with chronic hepatitis delta viral (HDV) ... enrolled at Ankara University Medical School, Turkey ... LOWR HDV - 1 (LOnafarnib With ... which randomized subjects to receive different doses of lonafarnib ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 3
... Inc. (Hologic or the Company) (NASDAQ: HOLX ... diagnostics products, medical imaging systems and surgical products dedicated ... the Company will host presentations for members of the ... North America) trade show in Chicago, IL. For more ...
... Ohio, Oct. 27, 2011 Mettler-Toledo International Inc. (NYSE: ... call to discuss the Company,s third-quarter results on Thursday, November ... live webcast of the call, visit www.mt.com/investors on ... available until November 7, 2011. METTLER TOLEDO ...
Cached Medicine Technology:Hologic to Host Investor Presentation at RSNA 2011 2
(Date:4/28/2015)... Santa Cruz, California (PRWEB) April 28, 2015 ... leader in premium, healthy, and convenient nutrition ... expansion of its distribution through United Natural ... distributor of natural, organic and specialty foods ... will now be available to thousands of ...
(Date:4/27/2015)... Churchview Supportive Living, a Gardant affordable ... and Fashion Show from 10:30 a.m. to noon on ... 2626 W. 63rd St. in Chicago, serves low-income older ... to maintain their independence. , “Mothers, grandmothers, godmothers and ... Day Brunch,” said Director of Marketing Elizabeth Clippard. , ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Women may ... from concussion, according to a new study published online ... mild traumatic brain injury (MTBI), is a common medical ... some individuals. , In most cases, patients who ... Ten to 15 percent of MTBI patients will continue ...
(Date:4/27/2015)... 2015 Jesse L. Goodman, M.D., M.P.H., ... Pharmacopeial Convention (USP) at the recently concluded Convention Meeting ... at Georgetown University and the Director of its Center ... As USP President, a volunteer position, Dr. Goodman will ... be a voting member, ex officio, of the Board ...
(Date:4/27/2015)... 27, 2015 Based in the Twin ... one of the few insurance marketing organizations in the ... and asset protection markets as well as employer sponsored ... afforded Secura Consultants the opportunity to consult with disability ... business easier and quicker. , An example of these ...
Breaking Medicine News(10 mins):Health News:LifeAID Beverage Co. Announces Expanded Distribution Roll Out Through UNFI -- United Natural Foods Inc. 2Health News:LifeAID Beverage Co. Announces Expanded Distribution Roll Out Through UNFI -- United Natural Foods Inc. 3Health News:Churchview Supportive Living Community in Chicago to Host Mother's Day Brunch 2Health News:Women Show Persistent Memory Impairment after Concussion 2Health News:Women Show Persistent Memory Impairment after Concussion 3Health News:Dr. Jesse Goodman Elected President of the USP Convention 2Health News:Simplified Solutions Now Makes Disability Insurance Business With Secura Consultants Even Easier! 2
... A recent research has found that the asthma epidemic in ... by adults over the past century . ,The study, ... is published this month in Annals of Allergy, Asthma & ... Asthma and Immunology (ACAAI). ,The pervasiveness of asthma ...
... a woman's reproductive history to start hormone therapy? How does ... is the most beneficial form of estrogen? ,These ... University of Wisconsin School of Medicine and Public Health hope ... of its kind, on the effects of estrogen therapy with ...
... tests using gene sequencing is able to help confirm ... the tools for much more accurate and rapid diagnosis. ... 40 inherited and potentially life-threatening disorders that cause enzymes ... to the accumulation of waste products that damage organs ...
... College London refutes the long-standing "runaway" theory on how HIV ... attacking T helper cells, a class of white blood cells ... long been puzzled as to why this process of depletion ... ,According to the "runaway" hypothesis, T cells infected ...
... documented the first case of virgin birth in cartilaginous fish, after ... aquarium, that had only female sharks which had no contact ... of the pup at Omaha's Henry Doorly Zoo, in the US, ... in one of the female sharks in the aquarium. ...
... Club of Calcutta will reach out to more poor people ... ,"All the three healthcare units we have opened in ... set a target to reach out to more number of ... functionary K.N. Gupta told a press conference Tuesday. ...
Cached Medicine News:Health News:Rise in Cigarette Use may Elucidate Asthma Epidemic in Children 2Health News:Effectiveness of Hormone Therapy During Menopause 2Health News:New DNA Tests Advances Treatment of Lysosomal Storage Diseases 2Health News:Study Refutes Theory on HIV's Effect on White Blood Cells 2
... as bone Gla protein, is a vitamin ... major component of the noncollagenous bone matrix ... bone, with a small amount produced by ... During bone formation, newly synthesized osteocalcin is ...
... Human Insulin-like growth factor binding protein-2 (IGFBP-2) ... IGFBPs have been proposed) which specifically bind ... IGF-II. The binding affinity of IGFBP-2 for ... than for IGF-I [1], suggesting a role ...
... produced in the adrenal gland and gonads, ... and estrone, both of which may be ... weak androgenic activity, estimated at ~(less than ... However, serum androstenedione levels often exceed testosterone ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
Medicine Products: